• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Il­lu­mi­na con­firms SEC has closed in­ves­ti­ga­tion in­to $8B Grail deal

5 hours ago
Pharma
Diagnostics

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

7 hours ago
Pharma

Il­lu­mi­na fore­casts $85M in tar­iff costs, de­crease in Chi­na sales

8 hours ago
Pharma
Diagnostics

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

9 hours ago
People
AI

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

9 hours ago
Pharma
Law

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

10 hours ago
Pharma
FDA+

FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment

10 hours ago
Pharma
FDA+

Bris­tol My­er­s' $40B US in­vest­ment; Sh­iono­gi to buy Japan­ese drug­mak­er

12 hours ago
Manufacturing

ALX On­col­o­gy won’t seek ap­proval for CD47 drug in gas­tric can­cer; Ko­r­ro Bio’s lay­offs

13 hours ago
News Briefing

Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff

13 hours ago
People

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

14 hours ago
R&D
Cell/Gene Tx

HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact

16 hours ago
Financing
Startups

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

17 hours ago
R&D

FDA will con­vene vac­cine ad­vi­sors to dis­cuss Covid strain up­dates

Yesterday
Pharma
FDA+

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

Yesterday
R&D
Pharma

Te­va plans staff cuts as it com­mits to ac­cel­er­at­ing growth

Yesterday
Pharma
Manufacturing

PhRMA says tar­iffs are 'not the an­swer' as in­dus­try trade probe clos­es for com­ments

Yesterday
Pharma
Manufacturing

FDA's ODAC will re­view drugs for four dif­fer­ent can­cers at meet­ing in May

Yesterday
Pharma
FDA+

Avadel can pur­sue la­bel ex­pan­sion for nar­colep­sy drug Lum­ryz af­ter court rul­ing

Yesterday
Pharma
Law

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Yesterday
Pharma

Com­pounders just lost their case to put obe­si­ty drug tirzepatide back in short­age

Yesterday
Pharma
Law

Charles Riv­er launch­es ‘strate­gic re­view’ along­side ac­tivist in­vestor El­liott

Yesterday
Outsourcing
Manufacturing

Eu­ro­pean reg­u­la­tors to re­view Val­ne­va shot; Jaz­z's stock dips on sub­par first-quar­ter rev­enue

Yesterday
News Briefing

Cedars-Sinai part­ners with Re­design Health to build health tech star­tups

Yesterday
Deals
Health Tech
1234 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.